Exhibit 99.01
Press Release www.shire.com |  |
Director/PDMR Shareholding
March 3, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company announces the release on March 2, 2010 of Ordinary Shares (“Shares”) and American Depository Shares (“ADSs”) in Shire plc in connection with Performance Share Awards (“PSP Awards”) granted in 2007 under Part B of the Shire Portfolio Share Plan (the “Plan”) to Persons Discharging Managerial Responsibility (“PDMR”).
In accordance with the rules of the Plan, the following Shares/ADSs were released:
| Name of PDMR | Type of security | Number of Shares/ADSs released | Number of Shares/ADSs sold to satisfy tax liabilities | ||
| Matthew Emmens (Director) | ADSs | 60,066 | 26,764 | ||
| Angus Russell (Director) | Shares | 68,277 | 27,038 | ||
| Tatjana May | Shares | 30,480 | 12,448 | ||
| Anita Graham | ADSs | 8,467 | 3,334 | ||
| Barbara Deptula | ADSs | 10,160 | 4,397 | ||
| Michael Cola | ADSs | 14,224 | 5,600 |
The PSP Awards for Matthew Emmens and Angus Russell were subject to performance criteria measured over the performance period 2007 to 2009. Based on the performance criteria, 84% of the PSP Awards vested.
All PDMRs sold sufficient Shares/ADSs, on March 2, 2010, at prices of £14.487 and $65.293 respectively, to satisfy tax liabilities as set out above.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
| Investor Relations | Cléa Rosenfeld (Rest of the World) | +44 1256 894 160 |
| Eric Rojas (North America) | +1 617 551 9715 |
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX